Nicholas R. Fragola

Nicholas R. Fragola

Auto-generated profile, based on publicly available information

Nicholas R. Fragola

Every Cure Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2023 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
NFNicholas R. Fragola
Nicholas R. Fragola
BBBrittany M. Brems
Brittany M. Brems
MMMunmun Mukherjee
Munmun Mukherjee
MCMeng Cui
Meng Cui
RBRaymond G. Booth
Raymond G. Booth
Many important physiological processes are mediated by alpha2A- and alpha2C-adrenergic receptors (α2Rs), a subtype of class A G protein-coupled receptors (GPCRs). However, α2R signaling is poorly understood, and there are few approved medications targeting these receptors. Drug discovery aimed at α2Rs is complicated by the high degree of binding pocket homology between α2AR and α2CR, which confounds ligand-mediated selective activation or inactivation of signaling associated with a particular subtype. Meanwhile, α2R signaling is complex and it is reported that activating α2AR is beneficial in many clinical contexts, while activating α2CR signaling may be detrimental to these positive effects. Here, we report on a novel 5-substituted-2-aminotetralin (5-SAT) chemotype that, depending on substitution, has diverse pharmacological activities at α2Rs. Certain lead 5-SAT analogues act as partial agonists at α2ARs, while functioning as inverse agonists at α2CRs, a novel pharmacological profile. Leads demonstrate high potency (e.g., EC50 < 2 nM) at the α2AR and α2CRs regarding Gαi-mediated inhibition of adenylyl cyclase and production of cyclic adenosine monophosphate (cAMP). To help understand the molecular basis of 5-SAT α2R multifaceted functional activity, α2AR and α2CR molecular models were built from the crystal structures and 1 μs molecular dynamics (MD) simulations and molecular docking experiments were performed for a lead 5-SAT with α2AR agonist and α2CR inverse agonist activity, i.e., (2S)-5-(2'-fluorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine (FPT), in comparison to the FDA-approved (for opioid withdrawal symptoms) α2AR/α2CR agonist lofexidine. Results reveal several interactions between FPT and α2AR and α2CR amino acids that may impact the functional activity. The computational data in conjunction with experimental in vitro affinity and function results provide information to understand ligand stabilization of functionally distinct GPCR conformations regarding α2AR and α2CRs.

2 April 2026 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
ELEmily Leung
Emily Leung
NFNicholas R. Fragola
Nicholas R. Fragola
ESElliott W. Sharp
Elliott W. Sharp
RHRebecca Harrison
Rebecca Harrison
EPErica Peterson
Erica Peterson
LCLuke Y. C. Chen
Luke Y. C. Chen
A combined clinical and computational pharmacophenomic study from the Coastal Rare Inflammatory Diseases Program and Every Cure.

12 March 2026 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
ESElliott W. Sharp
Elliott W. Sharp
NFNicholas Fragola
Nicholas Fragola
CBCharlotte Blewitt
Charlotte Blewitt
MGMatthew Goddeeris
Matthew Goddeeris
LLLee Lancashire
Lee Lancashire
DFDavid C. Fajgenbaum
David C. Fajgenbaum
Background: Despite the ultimate goal of medical researchers and funders being to maximize patient benefit, there is no systematic process for quantifying unmet medical need across diseases. While a relative unmet medical need scoring system would be valuable for prioritization of medical research, systematically performing this effort across all 22,701 human diseases is technically challenging, time-consuming, and expensive. Using a large language model-based (LLM) architecture, we built a scalable method demonstrating feasibility to quantify “unmet medical need” criteria across all diseases, combine those criteria into a single weighted score, and extend the method into new criteria or diseases in the future. We aimed to quantitatively determine which diseases have the greatest unmet medical need and, therefore, which diseases are priority targets for new repurposed treatments. Method and findings: We defined 11 scoring criteria across three categories of unmet medical need. For each criterion, we tested LLM models and refined prompts to generate a score per criteria for each disease and then defined a weighting for each criterion to contribute to a final score. A 30-disease development set was used to iterate on the prompting, and a 10-disease evaluation set was held out and used to evaluate the performance of the final prompt. All 22,701 human diseases in the MONDO disease ontology were quantitatively scored for their unmet medical need across all 11 weighted criteria. The resulting scores allowed for relative comparison between diseases of unmet medical needs. Inter-expert agreement was strong, indicating reliability of the scoring framework with 95% of ratings within a 1-point difference. Across multiple LLMs, gpt-4o is most closely aligned with expert rankings, achieving low mean and standard deviation differences relative to human scores. Furthermore, LLM-generated scores demonstrated strong Spearman’s rho correlations with expert assessments across key clinical criteria, such as mortality (ρ = 0.845) and quality-adjusted life years lost (ρ = 0.822), supporting their suitability for prioritizing unmet medical need. All data were generated in ~1 hour with no missing data, at a total cost of $120 USD of compute and the results of the Unmet Medical Need Index are publicly available. The main limitation of this study is the combined size of the development and evaluation set being 40 diseases. Conclusions: This accessible, scalable methodology enables funders and researchers, across governments, universities, healthcare organizations, and disease groups to tailor prioritization efforts according to unmet medical need in the context of their organizational objectives, by selecting appropriate criteria and weighting of those criteria. This method creates a pragmatic and transparent tool to streamline research prioritization. Future research should consider expanding the disease set size used to create scores.

27 April 2026 in Psychiatry Research Communications
Verified
Journal Article
Open access
NFNicholas R. Fragola
Nicholas R. Fragola
LLLee Lancashire
Lee Lancashire
JVJennifer K. Visser-Rogers
Jennifer K. Visser-Rogers
ESElliott W. Sharp
Elliott W. Sharp
CBCharlotte Blewitt
Charlotte Blewitt
DFDavid C. Fajgenbaum
David C. Fajgenbaum